Last reviewed · How we verify
HEV vaccine
At a glance
| Generic name | HEV vaccine |
|---|---|
| Also known as | Hecolin |
| Sponsor | Xiamen University |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of Hecolin® in Healthy Pregnant Women (PHASE2)
- Effectiveness Trial to Evaluate Protection of Pregnant Women by Hepatitis E Vaccine in Bangladesh. (PHASE4)
- Long-term Effectiveness of a Recombinant Hepatitis E Vaccine
- The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female
- The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female
- Safety and Immunogenicity of a Nipah Virus Vaccine (PHASE1)
- Immunogenicity and Safety of Co-immunization With Cecolin and Hecolin (PHASE4)
- Safety Study of Hepatitis E Vaccine (HEV239) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HEV vaccine CI brief — competitive landscape report
- HEV vaccine updates RSS · CI watch RSS
- Xiamen University portfolio CI